Sensitization of B-cell chronic lymphocytic leukemia cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligodeoxynucleotides

Blood

Volumn 99, Issue 4, 2002, Pages 1320-1326

  Decker, Thomas ^a,b   Hipp, Susanne ^a,b   Kreitman, Robert J ^a,b   Pastan, Ira ^a,b   Peschel, Christian ^a,b   Licht, Thomas ^a,b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYLTHIAZOL 2 YL) 5 (3 CARBOXYMETHOXYPHENYL) 2 (4 SULFOPHENYL) 2H TETRAZOLIUM; IMMUNOTOXIN; IMMUNOTOXIN LMB2; LMB 9; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; RECOMBINANT ANTIBODY; RECOMBINANT MONOCLONAL ANTIBODY CD22; RECOMBINANT MONOCLONAL ANTIBODY CD25; TETRAZOLIUM; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY COMBINING SITE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LEUKEMIA; CALORIMETRY; CELL ACTIVITY; CELL DEATH; CELL GROWTH; CELL SEPARATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; FLOW CYTOMETRY; HAIRY CELL LEUKEMIA; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IC 50; IMMUNOGENICITY; IMMUNOMAGNETIC SEPARATION; IMMUNOMODULATION; IMMUNOSTIMULATION; MALE; PRIORITY JOURNAL; RECEPTOR UPREGULATION; SENSITIZATION; T CELL LEUKEMIA;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; EXOTOXINS; FEMALE; HUMANS; IMMUNOTOXINS; LEUKEMIA, B-CELL, CHRONIC; MALE; MIDDLE AGED; OLIGODEOXYRIBONUCLEOTIDES; RECEPTORS, INTERLEUKIN-2; RECOMBINANT PROTEINS; THIONUCLEOTIDES; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 0037082476     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.4.1320     Document Type: Article

References (56)

1. Current concepts: Chronic lymphocytic leukemia
2. Advances in the biology and treatment of B-cell chronic lymphocytic leukemia
3. Apoptosis and cancer: Strategies for integrating programmed cell death
4. Redefining the therapeutic goals in chronic lymphocytic leukemia: Towards an evidence-based, risk adapted therapy
5. Peripheral blood stem cell (PBSC) mobilization and transplantation after fludarabine therapy in chronic lymphocytic leukemia (CLL): A report of the European Blood and Marrow Transplantation (EBMT) CLL subcomittee on behalf of the EBMT Chronic Leukemias Working Party (CLWP)
6. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma
7. Recombinant toxins for cancer treatment
8. Targeted toxins
9. Responses in refractory hairy cell leukemia to a recombinant immunotoxin
10. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies
11. A monclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells, I: Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells
12. A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin
13. Recombinant immunotoxins containing anti-Tac(Fv) and derivatives of Pseudomonas exotoxin produce complete regression in mice of an interleukin-2 receptor-expressing human carcinoma
14. Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli
15. Activity of immunotoxins constructed with modified Pseudomonas exotoxin A lacking the cell recognition domain
16. Cloning and expression of a gene segment encoding the enzymatic moiety of Pseudomonas aeruginosa exotoxin A
17. Functional analysis of domains II, Ib, and III of Pseudomonas exotoxin
18. 280 generates the enzymatically active fragment which translocates to the cytosol
19. Importance of the glutamate residue of KDEL in increasing the cytotoxicity of Pseudomonas exotoxin derivatives and for increased binding to the KDEL receptor
20. Domain II mutants of Pseudomonas exotoxin deficient in translocation
21. The N-terminal region of the 37-kDa translocated fragment of Pseudomonas exotoxin A aborts translocation by promoting its own export after microsomal membrane insertion
22. Apoptosis induced by immunotoxins used in the treatment of hematologic malignancies
23. The recombinant immunotoxin anti-Tac(Fv)-Pseudomonas exotoxin is cytotoxic toward peripheral blood malignant cells from patients with adult T-cell leukemia
24. Cytotoxic activities of recombinant immunotoxins composed of Pseudomonas exotoxin or diphteria toxin toward lymphocytes from patients with adult T-cell leukemia
25. Hairy cell leukemia, a B-cell neoplasm that is particularly sensitive to the cytotoxic effect of anti-Tac(Fv)-PE38 (LMB-2)
26. Recombinant toxins containing the variable domains of the anti-Tac monoclonal antibody to the interleukin-2 receptor kill malignant cells from patients with chronic lymphocytic leukemia
27. Bacterial CpG DNA activates immune cells to signal infectious danger
28. Causing a commotion in the blood: Immunotherapy progress from bacteria to bacterial DNA
29. Immune activation by bacterial DNA: A new genetic code
30. DNA activates human immune cells through a CpG sequence dependent manner
31. CpG DNA as a signal for growth, activation and maturation of human dendritic cells
32. CpG motifs in bacterial DNA trigger direct B-cell activation
33. Activation of human B cells by phosphorothioate oligonucleotides
34. Repeated administration of cytosine-phosphorothiolated gunanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity
35. CpG-DNA activates in vivo T cell epitope presenting dendritic cells to trigger protective antiviral cytotoxic T cell responses
36. Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma
37. The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides
38. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine secretion and an immunogenic phenotype in B-CLL patients
39. Immunostimulatory CpG-oligonucleotides induce the expression of functional IL-2 receptors on B-CLL cells: Costimulation with IL-2 results in a highly immunogenic phenotype
40. Molecular markers of B-cell lymphoma
41. CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturetion
42. Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors
43. A recombinant immunotoxin containing a disulfide-stabilized Fv fragment
44. Antitumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv fragment
45. Accumulation of a recombinant immunotoxin in a tumor in vivo: Fewer than 1000 molecules per cell are sufficient for complete responses
46. Increased cytotoxic activity of Pseudomonas exotoxin and two chimeric toxins ending in KDEL
47. Hematopoietic remodeling triggered by CpG DNA
48. Mechanism and function of a newly identified CpG DANN motif in human primary B cells
49. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo
50. Oligodeoxynucleotides enhance lipopolysaccharide-stimulated synthesis of tumor necrosis factor: Dependence on phosphorothioate modification and reversal by heparin
51. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization
52. Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice
53. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA
54. Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysacchances
55. Immunostimulatory DNA: Sequence-dependent production of potentially harmful or useful cytokines
56. CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens